iHuman Inc. Files 6-K Report

Ticker: IH · Form: 6-K · Filed: Sep 18, 2025 · CIK: 1814423

Ihuman INC. 6-K Filing Summary
FieldDetail
CompanyIhuman INC. (IH)
Form Type6-K
Filed DateSep 18, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: 6-K, filing, press-release

TL;DR

iHuman Inc. filed a 6-K on 9/18/25 with a press release attached.

AI Summary

iHuman Inc. filed a Form 6-K on September 18, 2025, reporting for the month of September 2025. The filing includes a press release as Exhibit 99.1. Vivien Weiwei Wang, Director and Chief Financial Officer, signed the report on behalf of the company.

Why It Matters

This filing indicates ongoing reporting activity for iHuman Inc., which is standard for publicly traded companies and provides updates to investors.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) that typically contains press releases or other periodic information, not material financial changes.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the registrant may be required to disclose to any stock exchange on which its securities are traded.

What is included in this specific 6-K filing?

This filing includes Exhibit 99.1, which is a Press Release.

Who signed this report on behalf of iHuman Inc.?

The report was signed by Vivien Weiwei Wang, Director and Chief Financial Officer.

What is the principal executive office address for iHuman Inc.?

The principal executive offices are located at Tower 306, No. 86 Beiyuan Road, Chaoyang District, Beijing 100101, People's Republic of China.

What is the SEC file number for iHuman Inc.?

The SEC file number for iHuman Inc. is 001-39591.

Filing Stats: 149 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2025-09-18 07:08:02

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. iHuman Inc. By : /s/ Vivien Weiwei Wang Name : Vivien Weiwei Wang Title : Director and Chief Financial Officer Date: September 18, 2025

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing